跳至主要内容
临床试验/NCT01588249
NCT01588249终止不适用

A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection

Zarbee's Inc.3 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2012年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
发起方
Zarbee's Inc.
入组人数
80
试验地点
3
主要终点
Change from baseline in cough frequency between the first night and the end of the second night.

研究概览

简要总结

Cough is a frequent symptom in children and infants and is one of the most common reasons parents visit a healthcare provider for their child. The US Food and Drug Administration has issued a warning that over-the-counter cough and cold medicines including antihistamines, decongestants, anti-tussives, and expectorants should not be administered to children younger than 2 years of age due not only to lack of proven efficacy, but also because of important safety concerns. A product that has been used in alternative medicine for cough is maple syrup. Although no studies have formally evaluated the use of maple syrup for nocturnal cough associated with URI, the demulcent effect of maple syrup may provide some relief from cough in children. A novel formulation of pasteurized maple cough syrup, when compared to placebo, should provide superior relief on nocturnal cough and the sleep difficulty associated with URI in children under 12 months and sleep difficulty of their parent/caregiver.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
— 至 12 Months(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Otherwise healthy male or female infant who is between 0 and 12 months of age.
  • •Presents to clinic with a URI characterized by the presence of rhinorrhea and cough for 7 or fewer days' duration.
  • •Patient is an appropriate candidate, in the judgment of the investigator, to participate in the study.
  • •Parents/caregivers provide an answer of at least "somewhat" (3 points on a 7-point Likert scale) for a minimum of 2 of the 3 questions related to nocturnal cough frequency, effect on child's sleep, and effect on parental/caregiver sleep based on the previous night's symptoms (see Section 11.0).
  • •Parent/legal authorized representative provides written informed consent for child to participate in study.
  • •Parent/caregiver who is willing and able to comply with study requirements.

排除标准

  • •Signs or symptoms of a more treatable disease (eg, asthma, pneumonia, laryngotrachebronchitis, sinusitis, allergic rhinitis).
  • •Diagnosis of influenza, bronchiolitis or respiratory syncytial virus (RSV).
  • •History of reactive airways disease, asthma, or chronic lung disease.
  • •Use of any medication to treat cough within 6 hours of bedtime on the evening prior to or on the day of enrollment. (Use of analgesic medications such as acetaminophen or ibuprofen is not exclusionary.)
  • •Presence of any significant disease including immunodeficiency, hepatic, renal, cardiovascular, or hematologic disease or any other health condition that, in the opinion of the investigator, would preclude participation in the study.

研究组 & 干预措施

Novel formulation of pasteurized maple cough syrup

Experimental

干预措施: Pasteurized maple syrup (Dietary Supplement)

Placebo

Placebo Comparator

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Change from baseline in cough frequency between the first night and the end of the second night.

时间窗: baseline and day 2

次要结局

未报告次要终点

研究者

发起方
Zarbee's Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验